Which has higher valuation and earnings, IRMD or LIVN?

iRadimed has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.75 $22.48M $1.79 50.36 LivaNova $1.43B 3.12 -$242.47M $1.95 41.71

Is IRMD or LIVN more profitable?

iRadimed has a net margin of 26.70% compared to LivaNova's net margin of 7.48%. iRadimed's return on equity of 23.73% beat LivaNova's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.73% 20.47% LivaNova 7.48% 16.48% 7.59%

Does the media favor IRMD or LIVN?

In the previous week, iRadimed had 9 more articles in the media than LivaNova. MarketBeat recorded 18 mentions for iRadimed and 9 mentions for LivaNova. LivaNova's average media sentiment score of 1.19 beat iRadimed's score of 0.63 indicating that LivaNova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LivaNova 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, NVST or IRMD?

Envista has higher revenue and earnings than iRadimed. iRadimed is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Envista $2.81B 1.59 $47M $0.41 66.99 iRadimed $83.81M 13.75 $22.48M $1.79 50.36

Is NVST or IRMD more profitable?

iRadimed has a net margin of 26.70% compared to Envista's net margin of 2.41%. iRadimed's return on equity of 23.73% beat Envista's return on equity. Company Net Margins Return on Equity Return on Assets Envista 2.41% 7.11% 3.91% iRadimed 26.70% 23.73% 20.47%

Does the media prefer NVST or IRMD?

In the previous week, iRadimed had 7 more articles in the media than Envista. MarketBeat recorded 18 mentions for iRadimed and 11 mentions for Envista. Envista's average media sentiment score of 1.03 beat iRadimed's score of 0.63 indicating that Envista is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Envista 7 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRadimed 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRMD or IRTC?

In the previous week, iRadimed had 9 more articles in the media than iRhythm Technologies. MarketBeat recorded 18 mentions for iRadimed and 9 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.09 beat iRadimed's score of 0.63 indicating that iRhythm Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRhythm Technologies 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is ESTA or IRMD more profitable?

iRadimed has a net margin of 26.70% compared to Establishment Labs' net margin of -19.05%. iRadimed's return on equity of 23.73% beat Establishment Labs' return on equity. Company Net Margins Return on Equity Return on Assets Establishment Labs -19.05% -218.77% -12.31% iRadimed 26.70% 23.73% 20.47%

Does the media prefer ESTA or IRMD?

In the previous week, iRadimed had 13 more articles in the media than Establishment Labs. MarketBeat recorded 18 mentions for iRadimed and 5 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.03 beat iRadimed's score of 0.63 indicating that Establishment Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Establishment Labs 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iRadimed 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, IRMD or WRBY?

iRadimed has higher earnings, but lower revenue than Warby Parker. iRadimed is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRadimed $83.81M 13.75 $22.48M $1.79 50.36 Warby Parker $890.57M 3.45 $1.64M $0.02 1,433.00

Is IRMD or WRBY more profitable?

iRadimed has a net margin of 26.70% compared to Warby Parker's net margin of 0.15%. iRadimed's return on equity of 23.73% beat Warby Parker's return on equity. Company Net Margins Return on Equity Return on Assets iRadimed 26.70% 23.73% 20.47% Warby Parker 0.15% 2.30% 1.18%

Does the media prefer IRMD or WRBY?

In the previous week, iRadimed had 12 more articles in the media than Warby Parker. MarketBeat recorded 18 mentions for iRadimed and 6 mentions for Warby Parker. Warby Parker's average media sentiment score of 0.98 beat iRadimed's score of 0.63 indicating that Warby Parker is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment iRadimed 3 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Warby Parker 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

iRadimed (IRMD) Competitors

$90.14 -0.72 (-0.79%)

As of 12:31 PM Eastern

Compare

IRMD vs. LIVN, NVST, IRTC, ESTA, and WRBY

Should you buy iRadimed stock or one of its competitors? MarketBeat compares iRadimed with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with iRadimed include LivaNova (LIVN), Envista (NVST), iRhythm Technologies (IRTC), Establishment Labs (ESTA), and Warby Parker (WRBY).

How does iRadimed compare to LivaNova?

iRadimed (NASDAQ:IRMD) and LivaNova (NASDAQ:LIVN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, risk, profitability, earnings, valuation and dividends.

iRadimed has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.75	$22.48M	$1.79	50.36
LivaNova	$1.43B	3.12	-$242.47M	$1.95	41.71

iRadimed has a net margin of 26.70% compared to LivaNova's net margin of 7.48%. iRadimed's return on equity of 23.73% beat LivaNova's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.73%	20.47%
LivaNova	7.48%	16.48%	7.59%

92.3% of iRadimed shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 34.6% of iRadimed shares are owned by company insiders. Comparatively, 0.4% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

iRadimed has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market. Comparatively, LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market.

In the previous week, iRadimed had 9 more articles in the media than LivaNova. MarketBeat recorded 18 mentions for iRadimed and 9 mentions for LivaNova. LivaNova's average media sentiment score of 1.19 beat iRadimed's score of 0.63 indicating that LivaNova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LivaNova	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed currently has a consensus price target of $120.00, indicating a potential upside of 33.12%. LivaNova has a consensus price target of $81.38, indicating a potential upside of 0.06%. Given iRadimed's stronger consensus rating and higher probable upside, equities analysts plainly believe iRadimed is more favorable than LivaNova.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
LivaNova	0 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.73

Summary

iRadimed beats LivaNova on 11 of the 16 factors compared between the two stocks.

How does iRadimed compare to Envista?

Envista (NYSE:NVST) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, risk, media sentiment and valuation.

Envista has higher revenue and earnings than iRadimed. iRadimed is trading at a lower price-to-earnings ratio than Envista, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Envista	$2.81B	1.59	$47M	$0.41	66.99
iRadimed	$83.81M	13.75	$22.48M	$1.79	50.36

Envista presently has a consensus target price of $28.62, indicating a potential upside of 4.18%. iRadimed has a consensus target price of $120.00, indicating a potential upside of 33.12%. Given iRadimed's stronger consensus rating and higher possible upside, analysts plainly believe iRadimed is more favorable than Envista.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Envista	0 Sell rating(s)	10 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Envista has a beta of 0.86, meaning that its stock price is 14% less volatile than the broader market. Comparatively, iRadimed has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

92.3% of iRadimed shares are owned by institutional investors. 1.0% of Envista shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

iRadimed has a net margin of 26.70% compared to Envista's net margin of 2.41%. iRadimed's return on equity of 23.73% beat Envista's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Envista	2.41%	7.11%	3.91%
iRadimed	26.70%	23.73%	20.47%

In the previous week, iRadimed had 7 more articles in the media than Envista. MarketBeat recorded 18 mentions for iRadimed and 11 mentions for Envista. Envista's average media sentiment score of 1.03 beat iRadimed's score of 0.63 indicating that Envista is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Envista	7 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRadimed	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

iRadimed beats Envista on 12 of the 17 factors compared between the two stocks.

How does iRadimed compare to iRhythm Technologies?

iRadimed (NASDAQ:IRMD) and iRhythm Technologies (NASDAQ:IRTC) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

iRadimed has a net margin of 26.70% compared to iRhythm Technologies' net margin of -3.53%. iRadimed's return on equity of 23.73% beat iRhythm Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.73%	20.47%
iRhythm Technologies	-3.53%	-10.26%	-1.39%

In the previous week, iRadimed had 9 more articles in the media than iRhythm Technologies. MarketBeat recorded 18 mentions for iRadimed and 9 mentions for iRhythm Technologies. iRhythm Technologies' average media sentiment score of 1.09 beat iRadimed's score of 0.63 indicating that iRhythm Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRhythm Technologies	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed currently has a consensus price target of $120.00, suggesting a potential upside of 33.12%. iRhythm Technologies has a consensus price target of $184.71, suggesting a potential upside of 50.48%. Given iRhythm Technologies' higher probable upside, analysts plainly believe iRhythm Technologies is more favorable than iRadimed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94

iRadimed has higher earnings, but lower revenue than iRhythm Technologies. iRhythm Technologies is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.75	$22.48M	$1.79	50.36
iRhythm Technologies	$747.14M	5.40	-$44.55M	-$0.86	N/A

92.3% of iRadimed shares are owned by institutional investors. 34.6% of iRadimed shares are owned by company insiders. Comparatively, 1.0% of iRhythm Technologies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

iRadimed has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market. Comparatively, iRhythm Technologies has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Summary

iRadimed beats iRhythm Technologies on 11 of the 17 factors compared between the two stocks.

How does iRadimed compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and iRadimed (NASDAQ:IRMD) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, valuation, risk, media sentiment, dividends and analyst recommendations.

iRadimed has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than iRadimed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$229.58M	12.22	-$51.06M	-$1.49	N/A
iRadimed	$83.81M	13.75	$22.48M	$1.79	50.36

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 92.3% of iRadimed shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by insiders. Comparatively, 34.6% of iRadimed shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Establishment Labs has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, iRadimed has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

iRadimed has a net margin of 26.70% compared to Establishment Labs' net margin of -19.05%. iRadimed's return on equity of 23.73% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
iRadimed	26.70%	23.73%	20.47%

In the previous week, iRadimed had 13 more articles in the media than Establishment Labs. MarketBeat recorded 18 mentions for iRadimed and 5 mentions for Establishment Labs. Establishment Labs' average media sentiment score of 1.03 beat iRadimed's score of 0.63 indicating that Establishment Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	2 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
iRadimed	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Establishment Labs presently has a consensus price target of $90.43, indicating a potential downside of 5.17%. iRadimed has a consensus price target of $120.00, indicating a potential upside of 33.12%. Given iRadimed's stronger consensus rating and higher probable upside, analysts clearly believe iRadimed is more favorable than Establishment Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

iRadimed beats Establishment Labs on 13 of the 17 factors compared between the two stocks.

How does iRadimed compare to Warby Parker?

iRadimed (NASDAQ:IRMD) and Warby Parker (NYSE:WRBY) are related companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

In the previous week, iRadimed had 12 more articles in the media than Warby Parker. MarketBeat recorded 18 mentions for iRadimed and 6 mentions for Warby Parker. Warby Parker's average media sentiment score of 0.98 beat iRadimed's score of 0.63 indicating that Warby Parker is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
iRadimed	3 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Warby Parker	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

iRadimed has a net margin of 26.70% compared to Warby Parker's net margin of 0.15%. iRadimed's return on equity of 23.73% beat Warby Parker's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRadimed	26.70%	23.73%	20.47%
Warby Parker	0.15%	2.30%	1.18%

92.3% of iRadimed shares are held by institutional investors. Comparatively, 93.2% of Warby Parker shares are held by institutional investors. 34.6% of iRadimed shares are held by insiders. Comparatively, 16.8% of Warby Parker shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

iRadimed currently has a consensus price target of $120.00, suggesting a potential upside of 33.12%. Warby Parker has a consensus price target of $29.82, suggesting a potential upside of 4.04%. Given iRadimed's stronger consensus rating and higher probable upside, analysts clearly believe iRadimed is more favorable than Warby Parker.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRadimed	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Warby Parker	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.64

iRadimed has higher earnings, but lower revenue than Warby Parker. iRadimed is trading at a lower price-to-earnings ratio than Warby Parker, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRadimed	$83.81M	13.75	$22.48M	$1.79	50.36
Warby Parker	$890.57M	3.45	$1.64M	$0.02	1,433.00

iRadimed has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Warby Parker has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market.

Summary

iRadimed beats Warby Parker on 11 of the 17 factors compared between the two stocks.

Get iRadimed News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRMD vs. The Competition

Export

Metric	iRadimed	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.15B	$5.69B	$6.80B	$12.66B
Dividend Yield	0.88%	1.79%	2.59%	10.03%
P/E Ratio	50.40	23.68	282.16	25.05
Price / Sales	13.75	58.86	576.18	79.91
Price / Cash	48.88	32.53	28.60	46.71
Price / Book	12.12	6.48	10.96	6.18
Net Income	$22.48M	$151.15M	$3.49B	$347.61M
7 Day Performance	-5.19%	2.99%	0.45%	0.71%
1 Month Performance	-10.72%	-1.58%	-4.26%	-3.75%
1 Year Performance	36.23%	4.54%	63.09%	20.17%

iRadimed Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRMD iRadimed	2.9216 of 5 stars	$90.15 -0.8%	$120.00 +33.1%	+37.3%	$1.15B	$83.81M	50.40	110	Earnings Report Dividend Announcement Gap Up
LIVN LivaNova	2.1183 of 5 stars	$81.60 +1.3%	$81.38 -0.3%	+94.8%	$4.48B	$1.43B	41.83	3,300	Positive News Upcoming Earnings
NVST Envista	2.5842 of 5 stars	$26.92 +1.1%	$28.54 +6.0%	+31.8%	$4.37B	$2.81B	65.53	12,000	Positive News Upcoming Earnings
IRTC iRhythm Technologies	4.2529 of 5 stars	$115.66 +3.1%	$184.71 +59.7%	-29.0%	$3.80B	$747.14M	N/A	2,400	Positive News Upcoming Earnings
ESTA Establishment Labs	2.0214 of 5 stars	$93.98 +2.0%	$90.43 -3.8%	+123.9%	$2.77B	$229.58M	N/A	1,004	Positive News Upcoming Earnings Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRMD) was last updated on 8/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

iRadimed (IRMD) Competitors

IRMD vs. LIVN, NVST, IRTC, ESTA, and WRBY

How does iRadimed compare to LivaNova?

Summary

How does iRadimed compare to Envista?

Summary

How does iRadimed compare to iRhythm Technologies?

Summary

How does iRadimed compare to Establishment Labs?

Summary

How does iRadimed compare to Warby Parker?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

iRadimed (IRMD) Competitors

IRMD vs. LIVN, NVST, IRTC, ESTA, and WRBY

How does iRadimed compare to LivaNova?

Which has higher valuation and earnings, IRMD or LIVN?

Is IRMD or LIVN more profitable?

Do insiders & institutionals have more ownership in IRMD or LIVN?

Which has more volatility and risk, IRMD or LIVN?

Does the media favor IRMD or LIVN?

Do analysts recommend IRMD or LIVN?

Summary

How does iRadimed compare to Envista?

Which has preferable earnings & valuation, NVST or IRMD?

Do analysts recommend NVST or IRMD?

Which has more risk and volatility, NVST or IRMD?

Do institutionals & insiders believe in NVST or IRMD?

Is NVST or IRMD more profitable?

Does the media prefer NVST or IRMD?

Summary

How does iRadimed compare to iRhythm Technologies?

Is IRMD or IRTC more profitable?

Does the media favor IRMD or IRTC?

Do analysts prefer IRMD or IRTC?

Which has preferable earnings and valuation, IRMD or IRTC?

Do institutionals and insiders hold more shares of IRMD or IRTC?

Which has more risk and volatility, IRMD or IRTC?

Summary

How does iRadimed compare to Establishment Labs?

Which has preferable valuation & earnings, ESTA or IRMD?

Do institutionals & insiders believe in ESTA or IRMD?

Which has more volatility & risk, ESTA or IRMD?

Is ESTA or IRMD more profitable?

Does the media prefer ESTA or IRMD?

Do analysts prefer ESTA or IRMD?

Summary

How does iRadimed compare to Warby Parker?

Does the media prefer IRMD or WRBY?

Is IRMD or WRBY more profitable?

Do insiders and institutionals have more ownership in IRMD or WRBY?

Do analysts prefer IRMD or WRBY?

Which has better valuation & earnings, IRMD or WRBY?

Which has more volatility and risk, IRMD or WRBY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRMD vs. The Competition

iRadimed Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools